Ren X, Deng L, Dong X, Bai Y, Li G, Wang Y
Int J Immunopathol Pharmacol. 2024; 38:3946320241305390.
PMID: 39660594
PMC: 11632882.
DOI: 10.1177/03946320241305390.
Hwang H, Lee T
PLoS One. 2023; 18(11):e0294649.
PMID: 37983233
PMC: 10659172.
DOI: 10.1371/journal.pone.0294649.
Butel-Simoes L, Haw T, Williams T, Sritharan S, Gadre P, Herrmann S
Hypertension. 2023; 80(4):685-710.
PMID: 36756872
PMC: 10023512.
DOI: 10.1161/HYPERTENSIONAHA.122.17947.
Zullig L, Sung A, Khouri M, Jazowski S, Shah N, Sitlinger A
JACC CardioOncol. 2022; 4(2):149-165.
PMID: 35818559
PMC: 9270612.
DOI: 10.1016/j.jaccao.2022.03.005.
Scott S, Greenlee A, Matzko A, Stein M, Naughton M, Zaramo T
Heart Fail Clin. 2022; 18(3):425-442.
PMID: 35718417
PMC: 10391230.
DOI: 10.1016/j.hfc.2022.02.003.
VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
Camarda N, Travers R, Yang V, London C, Jaffe I
Curr Oncol Rep. 2022; 24(4):463-474.
PMID: 35179707
PMC: 9218917.
DOI: 10.1007/s11912-022-01224-0.
Application of apatinib after multifaceted therapies for metastatic breast cancer.
Wang J, Chen Y, Chen R, Wu L, Cheng J
Transl Cancer Res. 2022; 9(8):4488-4497.
PMID: 35117814
PMC: 8797807.
DOI: 10.21037/tcr-19-2588.
Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs.
Coschignano M, De Ciuceis C, Agabiti-Rosei C, Brami V, Rossini C, Chiarini G
Front Cardiovasc Med. 2021; 8:651594.
PMID: 33778028
PMC: 7987651.
DOI: 10.3389/fcvm.2021.651594.
The hypertensive effect of sorafenib is abolished by sildenafil.
Dabire H, Drame F, Cita N, Ghaleh B
Cardiooncology. 2020; 6:7.
PMID: 32685197
PMC: 7358208.
DOI: 10.1186/s40959-020-00064-w.
Nuances to precision dosing strategies of targeted cancer medicines.
Hopkins A, Menz B, Wiese M, Kichenadasse G, Gurney H, McKinnon R
Pharmacol Res Perspect. 2020; 8(4):e00625.
PMID: 32662214
PMC: 7358594.
DOI: 10.1002/prp2.625.
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona S, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M
Oncotarget. 2020; 11(23):2172-2181.
PMID: 32577163
PMC: 7289535.
DOI: 10.18632/oncotarget.27612.
[Austrian Consensus on High Blood Pressure 2019].
Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt M
Wien Klin Wochenschr. 2019; 131(Suppl 6):489-590.
PMID: 31792659
DOI: 10.1007/s00508-019-01565-0.
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
Sun Y, Yang L, Hao X, Liu Y, Zhang J, Ning Z
J Hematol Oncol. 2019; 12(1):9.
PMID: 30642372
PMC: 6332596.
DOI: 10.1186/s13045-018-0695-0.
Treatment-related toxicities of apatinib in solid tumors: a meta-analysis.
Peng L, Ye X, Hong Y, Zhang J, Dong Y, Zhao Q
Oncotarget. 2018; 9(63):32262-32270.
PMID: 30181815
PMC: 6114950.
DOI: 10.18632/oncotarget.24215.
Management of VEGF-Targeted Therapy-Induced Hypertension.
Caletti S, Paini A, Coschignano M, De Ciuceis C, Nardin M, Zulli R
Curr Hypertens Rep. 2018; 20(8):68.
PMID: 29959593
DOI: 10.1007/s11906-018-0871-1.
Hypertension in malignancy-an underappreciated problem.
Malyszko J, Malyszko M, Kozlowski L, Kozlowska K, Malyszko J
Oncotarget. 2018; 9(29):20855-20871.
PMID: 29755695
PMC: 5945504.
DOI: 10.18632/oncotarget.25024.
The Impact of Pazopanib on the Cardiovascular System.
Justice C, Derbala M, Baich T, Kempton A, Guo A, Ho T
J Cardiovasc Pharmacol Ther. 2018; 23(5):387-398.
PMID: 29706106
PMC: 6257996.
DOI: 10.1177/1074248418769612.
Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.
Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T
Oncotarget. 2018; 9(20):15219-15227.
PMID: 29632638
PMC: 5880598.
DOI: 10.18632/oncotarget.24635.
Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients.
Niinivirta M, Enblad G, Edqvist P, Ponten F, Dragomir A, Ullenhag G
J Cancer. 2017; 8(19):3975-3983.
PMID: 29187872
PMC: 5705999.
DOI: 10.7150/jca.20889.
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R
Drugs R D. 2017; 17(4):585-596.
PMID: 28895069
PMC: 5694422.
DOI: 10.1007/s40268-017-0209-5.
